Cenix BioScience Signs Framework Research Agreement with AstraZeneca for RNAi-Based Drug Discovery
News Mar 20, 2008
Cenix BioScience GmbH (Dresden) has announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP to advance the latter’s efforts in the discovery and validation of novel therapeutic drug targets.
Cenix will apply its well-established expertise in combining high throughput (HT) applications of RNAi-based gene silencing, the technology behind the 2006 Nobel Prize for Medicine, with high content phenotypic analyses in cultured human cells.
The initial project will involve a HT-RNAi screen using an assay strategy co-designed with AstraZeneca scientists to discover and validate novel oncology targets. Cenix will adapt and implement multi-parametric microscopy-based assays using the Cellenger image analysis platform from Munich-based Definiens, to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes. Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for discovering and prioritizing targets for therapeutic drug development in a wide range of disease fields.
“We are very excited to begin working with AstraZeneca scientists to help advance their discovery pipeline with this powerful and well-proven technology,” said Dr. Christophe Echeverri, CEO/CSO of Cenix.
“We look forward to driving this relationship beyond the initial pilot through to multiple projects, as we have successfully done with other major pharma partners: by exceeding expectations on scientific and strategic excellence, and delivering the most detailed and professional reporting available in this field,” Dr. Echeverri added.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE